SEC FILINGS


Form 424B5
ACADIA PHARMACEUTICALS INC filed this Form 424B5 on 11/26/2018
Document Outline
Entire Document (642.5 KB)
Subdocument 1 - 424B5 - 424B5
Page 1 - Filed Pursuant to Rule 424(b)(5)
Page 2 - TABLE OF CONTENTS
Page 3 - ABOUT THIS PROSPECTUS SUPPLEMENT
Page 4 - PROSPECTUS SUPPLEMENT SUMMARY
Page 5 - N/A
Page 6 - Corporate Information
Page 7 - The Offering
Page 8 - RISK FACTORS
Page 9 - NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 10 - USE OF PROCEEDS
Page 11 - DILUTION
Page 12 - N/A
Page 13 - UNDERWRITING
Page 14 - Option to Purchase Additional Shares
Page 15 - Passive Market Making
Page 16 - Notice to Prospective Investors in the European Economic Area
Page 17 - Notice to Prospective Investors in Switzerland
Page 18 - Notice to Prospective Investors in Australia
Page 19 - Notice to Prospective Investors in Singapore
Page 20 - Notice to Prospective Investors in the British Virgin Islands
Page 21 - Notice to Prospective Investors in Taiwan
Page 22 - N/A
Page 23 - LEGAL MATTERS
Page 24 - N/A
Page 25 - PROSPECTUS
Page 26 - TABLE OF CONTENTS
Page 27 - ACADIA PHARMACEUTICALS INC.
Page 28 - N/A
Page 29 - RISK FACTORS
Page 30 - If we do not obtain regulatory approval of NUPLAZID for other indications in the United States, or f
Page 31 - N/A
Page 32 - NUPLAZID has only been studied in a limited number of patients and in limited populations. As we con
Page 33 - If we are unable to effectively train and equip our sales force, our ability to successfully commerc
Page 34 - Our ability to generate product revenues will be diminished if NUPLAZID does not receive coverage fr
Page 35 - Healthcare reform measures may negatively impact our ability to sell NUPLAZID or our product candida
Page 36 - N/A
Page 37 - We are subject, directly and indirectly, to federal, state and foreign healthcare laws and regulatio
Page 38 - N/A
Page 39 - If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Progr
Page 40 - The FDA granted marketing approval of NUPLAZID for the treatment of hallucinations and delusions ass
Page 41 - If we fail to obtain the capital necessary to fund our operations, we will be unable to successfully
Page 42 - The pivotal Phase 3 study with NUPLAZID for PD Psychosis, the results of which were announced in Nov
Page 43 - We do not have a partner for the development of pimavanserin, and are solely responsible for the adv
Page 44 - Delays, suspensions and terminations in our clinical trials could result in increased costs to us an
Page 45 - We previously have depended, and in the future may depend, on collaborations with third parties to d
Page 46 - We rely on third parties to conduct our clinical trials and perform data collection and analysis, wh
Page 47 - We currently depend, and in the future will continue to depend, on third parties to manufacture NUPL
Page 48 - If we are unable to attract, retain, and motivate key management, research and development, and sale
Page 49 - We have recently increased the size of our organization, and will need to continue to increase the s
Page 50 - If we fail to develop, acquire or in-license other product candidates or products, our business and
Page 51 - We expect that our results of operations will fluctuate, which may make it difficult to predict our
Page 52 - The recently passed comprehensive tax reform bill could adversely affect our business and financial
Page 53 - We may not be able to continue or fully exploit our collaborations with outside scientific and clini
Page 54 - Earthquake or fire damage to our facilities could delay our research and development efforts and adv
Page 55 - N/A
Page 56 - Confidentiality agreements with employees and others may not adequately prevent disclosure of our tr
Page 57 - N/A
Page 58 - The patent applications of pharmaceutical and biotechnology companies involve highly complex legal a
Page 59 - Risks Related to Our Industry
Page 60 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 61 - Risks Related to Our Common Stock
Page 62 - If we or our stockholders sell substantial amounts of our common stock, the market price of our comm
Page 63 - If our officers, directors, and largest stockholders choose to act together, they may be able to sig
Page 64 - We do not intend to pay dividends on our common stock in the foreseeable future; as such, you must r
Page 65 - NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 66 - USE OF PROCEEDS
Page 67 - PLAN OF DISTRIBUTION
Page 68 - LEGAL MATTERS
Page 69 - WHERE YOU CAN FIND MORE INFORMATION
Page 70 - Common Stock